G2B receives funding to accelerate its transfer to the market and society

Gate2Brain, a spin-off of Sant Joan de Déu (SJD), Institute for Research in Biomedicine (IRB) Barcelona and University of Barcelona (UB) will develop a new drug using a shuttle peptide that crosses the blood-brain barrier (BBB) to improve treatments for pediatric brain cancer.

.  has been awarded 300,000 euro funding by the 2021 CaixaResearch Consolidate call. With this award, “la Caixa” Foundation will help Gate2Brain to advance its technology and reach the society. The ultimate goal of this project is to enhance the health and quality of life of children with brain tumors such as diffuse intrinsic pontine glioma (DIPG).

DIPG is the most severe type of brain cancer, and it affects approximately two children per million yearly. Currently, there is no cure or effective treatment for this disease, and the median survival after diagnosis is only 8-11 months.

Although certain drugs show potent anticancer activity against DIPG in vitro, all of them have failed in clinical trials. The likely reason for such failure is that they cannot cross the BBB to reach the tumor. The BBB is a protective cellular barrier that allows only certain molecules from the circulating blood to get into the brain, and it prevents pathogens and other substances, including most anticancer medicines, from entering.

The spin-off Gate2Brain has designed a shuttle peptide that can carry drugs across the BBB to treat DIPG and other brain diseases. The company aims to carry out the preclinical validation of the new drug G2B-002. Gate2Brain shuttles can be adapted to a wide range of molecules, showing enormous potential to treat various brain diseases.

“Humankind has always dreamt of reaching the outer space and also the inside of our brain. At Gate2Brain, we dream of helping drugs enter the brain and thus of being able to treat pediatric cancers such as DIPG.”

Gate2Brain was launched in 2020, founded by Dr. Meritxell Teixidó, CEO of the company, with the participation of SJD Barcelona Children’s Hospital, SJD Research Foundation, IRB Barcelona and UB. The Mind the Gap Program of the Botín Foundation invested €500,000 and endorsed the project through the incorporation of one expert entrepreneur as advisor. Shortly after its launching, the company received additional support from the BStartup Health Program of Banco Sabadell (€100,000). Located at the Barcelona Science Park, Gate2Brain collaborates actively with the Pediatric Cancer Program at the Institut de Recerca Sant Joan de Déu.

GATE2BRAIN AND ANOTHER THREE INNOVATIVE BIOMEDICAL PROJECTS ARE STRENGTHENED BY THE SUPPORT FROM “LA CAIXA” FOUNDATION

In addition to the Gate2Brain project, other awardees include one project to develop synthetic cells for viral infections, a technological approach to overcome resistance and recurrence of cancer stem cells, and intelligent glasses to correct serious eye defects.

Beyond the funding of up to €300,000 per project, the awardees receive support in technology transfer, funding tools and negotiations, and mentorship by experts that help define personalized development and commercialization plans.

The 2021 CaixaResearch Consolidate call supported these projects to promote the transfer of knowledge and technologies in the field of biomedicine and health and to provide support for the creation of new research-based companies. The call remains open throughout the year to ensure that applicant projects receive adequate funding in a timely manner.

Source: https://www.irsjd.org/en/news-and-events/news/836/gate2brain-receives-funding-from-la-caixa-foundation-to-accelerate-its-transfer-to-the-market-and-society

 

/by
You might also like
‘Tractor’ proteins that carry drugs to the brain as therapy for incurable pediatric cancer
CaixaImpulsGate2Brain as alumni at Caixa Impulse Validate
Gate2Brain participated on June 29 at The Milner Therapeutics Institute (MTI) Pitch Day 🗣️at the University of Cambridge, the cradle of cancer research. The MTI Pitch Day is a great initiative designed to highlight companies like us to investors, to create connections between academic entrepreneurship and investment to promote therapeutic companies. A great event that pulls together on one side academic, preclinical and research and on the other industry in an effort to push forward collaborative drug development and increase the standard of patient careGate2Brain at MIT Pitch Day at University of Cambridge
Three University of Barcelona spin-offs led by women will receive funding as part of the Women TechEU pilot callFundació Bosch i GimperaThree University of Barcelona spin-offs will receive funding from Women TechEU pilot call
Grit International Female Accelerator!Grit International Female AcceleratorG2B joined the Grit International Female Accelerator
It’s Gate2Brain second anniversary!! 🎂 The creativity, work and dedication of Gate2Brain's team can only be matched with its desire to bring medicines beyond barriers.Gate2BrainGate2Brain second anniversary
Nadia Calviño, First Vice President of the Government and Minister of Economic Affairs visits Gate2BrainSJDNadia Calviño, First Vice President of the Government visits Gate2Brain
Gate2Brain will be attending in Basel, Switzerland, the Investment Readiness Series, a @Biocat initiative co-organized by the Delegation of the Government of Catalonia in Switzerland, The aim of the meeting is to put the best projects - from companies and/or research organizations - in contact with investors, business angels, venture capitalists and leading Swiss companies.Gate2Brain will be attending The Investment Readiness Series
Gate2Brain

Gate2Brain is a biotech company focused on the development of therapeutics that efficiently cross biological barriers such as the blood-brain barrier. We use a radically innovative peptide-based patented technology.

Where to find us

Barcelona Scientific Park
Baldiri Reixac, 4-8, Torre I
08028 Barcelona, Spain
info@gate2brain.com

Social

Four innovative biomedical projects boosted by the Fundació “la Caix...Cuatro proyectos biomédicos innovadores reciben el impulso de la Fundación ”la Caixa” para acelerar su llegada al mercado y a la sociedadFundació La Caixa¿Cómo transportar fármacos al cerebro para tratar patologías?La VanguardiaHow to transport drugs to the brain to treat pathologies?